Rachel Derr is an Endocrinology/Metabolic physician affiliated with Grand Valley State University. OpenAlex indexes 33 publications with 1,928 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
975 Johnson Fy Rd NE
Suite 400
Atlanta, GA 303421619
Telephone
404-843-4000Provider last certified this registry record 28 Aug 2020.
Industry payments
58 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202521 payments
- Lilly USA, LLCProgram year202518 payments
- Novo Nordisk IncProgram year202516 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
71.4%RANK Ligand Inhibitor71.3%Denosumab100%Prolia0%Part D + Part B<11 patientsOther drugs affecting bone structure and mineralization0.1%Crysvita100%Part D<11 patientsMetabolism & gastrointestinal
16.2%GLP-1 receptor agonist5.8%Ozempic55%Mounjaro42%Rybelsus2%Trulicity1%Part D<11 patientsInsulin Analog5.2%Lantus Solostar15%Tresiba Flextouch U-10014%Novolog Flexpen11%Tresiba Flextouch U-20010%Fiasp Flextouch9%Toujeo Solostar8%Basaglar Kwikpen U-1007%Humalog Kwikpen U-1006%Humalog4%Novolog4%Insulin Lispro Kwikpen U-1002%Admelog Solostar2%Toujeo Max Solostar2%Fiasp2%Soliqua 100-332%Lantus2%Part D<11 patients+ 7 more classes in this area
Hormonal (systemic)
9%l-Thyroxine7.6%Levothyroxine Sodium55%Synthroid43%Levoxyl2%Part D<11 patientsl-Triiodothyronine0.7%Liothyronine Sodium100%Part D≥29 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus2016
- Threat Assessment and Risk Analysis: An Applied Approach2015
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”